Finishing HIV prevention study
Part of Immune system & allergy, Infections clinical trials.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 54 years old
- You are a cis-gender male (assigned male at birth and identify as a man)
- You have had at least one of these HIV risk behaviors in the last 6 months: a bacterial STI (like syphilis, gonorrhea, or chlamydia), sex with a partner living with HIV, condomless sex with two or more partners whose HIV status was unknown, or injection drug use with shared equipment
- You are HIV-negative (confirmed by self-report and willing to test)
- You are Latinx/Hispanic (required for this study)
- You are not currently taking PrEP (oral or injectable) and have not taken it in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
This study tests a behavioral program to help men who have sex with men start using PrEP, a daily pill that prevents HIV. It is designed for those at high risk for HIV who have not used PrEP before.
This study looks at how taking PrEP (medicine to prevent HIV) affects HIV prevention and how much it costs in real life. You may be able to join if you are HIV-negative and are interested in starting, currently using, or have used PrEP before.
This study helps transgender women who are not regularly using PrEP (a daily pill to prevent HIV) get access to HIV prevention services. It uses a smartphone to take pictures and connect with support.
This study tests a program called PrEP Choice to help young people learn about and start PrEP, a daily pill that prevents HIV. It aims to see if offering choices in PrEP care makes it easier to use.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.